Get the Stockscreener App
9.06
0.22%
-0.02
After Hours:
9.06
Neuropace Inc stock is traded at $9.06, with a volume of 132.24K.
It is down -0.22% in the last 24 hours and down -14.53% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$9.08
Open:
$9.21
24h Volume:
132.24K
Relative Volume:
0.39
Market Cap:
$297.15M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-7.1339
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
-4.83%
1M Performance:
-14.53%
6M Performance:
-24.31%
1Y Performance:
+24.11%
1-Day Range:
$9.01
$9.36
1-Week Range:
$8.9688
$9.6402
52-Week Range:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
9.06 | 333.56M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
123.67 | 232.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.64 | 153.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
389.40 | 150.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.61 | 114.55B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.49 | 46.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
What drives NeuroPace Inc. stock priceAccelerated profit realization - Jammu Links News
NeuroPace secures $75M credit facility with MidCap Financial - MSN
(NPCE) Proactive Strategies - news.stocktradersdaily.com
How NeuroPace Inc. stock performs during market volatilityFree Stock Selection - Newser
What makes NeuroPace Inc. stock price move sharplyFree Stock Tips Group - Newser
Why NeuroPace Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace’s SWOT analysis: innovative epilepsy treatment stock faces growth hurdles By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
NeuroPaceVolatile, Uncertain, But Promising (NASDAQ:NPCE) - Seeking Alpha
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey - MSN
NeuroPace Inc (NPCE) Trading Down 3.93% on Jun 27 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - WV News
GAMMA Investing LLC Acquires Shares of 4,326 NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm - WV News
NeuroPace's NAUTILUS Fallout: A Shareholder's Guide to Fraud Claims and Recovery - AInvest
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load? - simplywall.st
Metric Analysis: NeuroPace Inc (NPCE)’s Key Ratios in the Limelight - DWinneX
Two Sigma Investments LP Invests $293,000 in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
Cantor Fitzgerald Comments on NeuroPace FY2026 Earnings - MarketBeat
Bank of America Corp DE Raises Position in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect - ACCESS Newswire
Research Analysts Set Expectations for NeuroPace Q2 Earnings - MarketBeat
NeuroPace Holds Virtual Annual Stockholders Meeting - TipRanks
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges By Investing.com - Investing.com South Africa
NeuroPace’s SWOT analysis: med tech stock poised for growth amid challenges - Investing.com
NeuroPace Inc (NPCE) Shares Down 3.25% on Jun 12 - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) - ACCESS Newswire
NeuroPace stock maintains buy rating at UBS following physician survey By Investing.com - Investing.com India
NeuroPace stock maintains buy rating at UBS following physician survey - Investing.com
Cantor Fitzgerald Estimates NeuroPace FY2026 Earnings - Defense World
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Makes New Investment in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Q2 Earnings Forecast for NeuroPace Issued By Leerink Partnrs - Defense World
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.28%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):